BUZZ-Australia's Dimerix hits 7-month high on $4.8 billion sale

Reuters12-22 12:10
BUZZ-Australia's Dimerix hits 7-month high on $4.8 billion sale 

** Shares of Dimerix DXB.AX rise as much as 12.5% to A$0.63, its highest level in seven months

** Stock touches its biggest intraday pct gain in six months, if gains hold

** Biotech co says U.S. listed biotech firm, BioMarin Pharmaceutical BMRN.O to acquire co's U.S. commercial licensing partner, Amicus Therapeutics for $4.8 billion

** Amicus Therapeutics is a biopharma co, licensing DXB's drug, DMX-200, for U.S. market to treat rare kidney diseases

** Stock up 80.89% YTD, including session's moves

(Reporting by Aamir Sheik Khalid in Bengaluru)

((Aamir.SheikKhalid@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment